(Q51164834)

31 March 2018

editorial

0 references

title

Innovation in safety pharmacology testing. (English)

1 reference

31 March 2018

1 reference

M K Pugsley

1

1 reference

31 March 2018

R Towart

2

1 reference

31 March 2018

S Authier

3

1 reference

31 March 2018

D J Gallacher

4

1 reference

31 March 2018

M J Curtis

5

1 reference

31 March 2018

publication date

27 May 2011

1 reference

31 March 2018

Journal of Pharmacological and Toxicological Methods

published in

1 reference

31 March 2018

volume

64

1 reference

31 March 2018

issue

1

1 reference

31 March 2018

page(s)

1-6

1 reference

31 March 2018

Principles of drug abuse liability assessment in laboratory animals

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Cardiovascular and respiratory safety pharmacology in Göttingen minipigs: Pharmacological characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Combined cardiopulmonary assessments with implantable telemetry device in conscious freely moving cynomolgus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Replacement of animal procedures: alternatives in research, education and testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Origins, practices and future of safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Evaluation of an algorithm for highly automated measurements of QT interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Tissue slices from adult mammalian hearts as a model for pharmacological drug testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

10th annual meeting of the Safety Pharmacology Society: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

ECG arrhythmias in non-implanted vs. telemetry-implanted dogs: need for screening before and sufficient recovery time after implantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

The RETHINK project: impact of toxicity testing in the minipig as an alternative approach in regulatory toxicity testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Limited antifibrillatory effectiveness of clinically relevant concentrations of class I antiarrhythmics in isolated perfused rat hearts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

The RETHINK project--minipigs as models for the toxicity testing of new medicines and chemicals: an impact assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Continuous evaluation of drug withdrawal in the rat using telemetry: effects of morphine and chlordiazepoxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

The 'overly-sensitive' heart: sodium channel block and QRS interval prolongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Ventricular rate adaptation: a novel, rapid, cellular-based in-vitro assay to identify proarrhythmic and torsadogenic compounds.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

On the relationship between block of the cardiac Na⁺ channel and drug-induced prolongation of the QRS complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

A quantitative description of membrane current and its application to conduction and excitation in nerve

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Modelling the long QT syndrome with induced pluripotent stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Sensitivity of two noninvasive blood pressure measurement techniques compared to telemetry in cynomolgus monkeys and beagle dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Patient-specific induced pluripotent stem-cell models for long-QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

An integrated cardiovascular and neurobehavioural functional assessment in the conscious telemetered cynomolgus monkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Current approaches and issues in non-clinical evaluation of abuse and dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

How good are current approaches to nonclinical evaluation of abuse and dependence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Functional biomarkers of musculoskeletal syndrome (MSS) for early in vivo screening of selective MMP-13 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

New perspectives in CNS safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Principles of safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Non-clinical models: validation, study design and statistical consideration in safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Trends in safety pharmacology: posters presented at the annual meetings of the Safety Pharmacology Society 2001-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

High Definition Oscillometry: a novel technique for non-invasive blood pressure monitoring in the cynomolgus monkey (Macaca fascicularis).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Learning versus confirming in clinical drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Measuring high pressure baroreceptor sensitivity in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Using pharmacokinetic modeling to determine the effect of drug and food on gastrointestinal transit in dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Integrated risk assessment and predictive value to humans of non-clinical repolarization assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Effects of calcium ions and local anesthetics on electrical properties of Purkinje fibres.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2011.05.005

10.1016/J.VASCN.2011.05.005

7 January 2021

Identifiers

DOI

1 reference

31 March 2018

1 reference

31 March 2018